Genetic Cancer Research Fund
Dr. Goldberg is one of America's Best Doctors. He has been listed in U.S.News and World Re-port's Top Doctors for multiple consecutive years. He has also been listed in Who's Who in Med-ical Sciences Education and in Best Doctors since 2001.He led a national intergroup study N9741 as part of an international phase III study of oxaliplatin, irinotecan and 5-fluorouracil in combinations for first-line treatment of advanced colorectal cancer. This study, which resulted in approval of oxaliplatin for clinical use, was conducted in centers across the United States and Canada, and helped change the standard of care for patients with advanced colorectal cancer. Dr. Goldberg's clinical interests include managing patients with gastrointestinal (GI) cancers with a focus on colorectal, carcinoid and GI tract neuroendocrine cancers, new drug development and inherited predisposition to GI cancers.
Each year, 6,026 Ohioans are diagnosed with colorectal cancer. Lynch syndrome is the most common hereditary cause of colorectal and endometrial cancer. Previous work done at the James by Dr. Albert de la Chapelle and Heather Hampel, MS, CGC has shown that 1 out of every 35 colorectal cancer patients and in 1 out of every 40 endometrial cancer patients has Lynch syndrome. In addition, many of their relatives will also have Lynch syndrome and very high risks for cancer. There is evidence that early cancer surveillance and prevention strategies can prevent cancers and save lives in these high risk individuals. The current study plans to test approximately 4,000 colorectal cancer patients in Ohio to prove that this screening can be done on a large scale basis and to determine the best approach to doing this screening so that it can be implemented nationally. It is calculated that a minimum of 120 of these patients and 360 of their relatives will have LS. As a result, 480 individuals will be diagnosed with Lynch syndrome as part of this study and will be able to benefit from appropriate medical management. Dr. Goldberg will be involved in developing therapeutic studies for the colorectal cancer patients that are found to be more likely to have Lynch syndrome (800) and in the identification of new colorectal can-cer genes.